Your browser doesn't support javascript.
loading
Overcoming the blood-brain barrier by Annexin A1-binding peptide to target brain tumours.
Nonaka, Motohiro; Suzuki-Anekoji, Misa; Nakayama, Jun; Mabashi-Asazuma, Hideaki; Jarvis, Donald L; Yeh, Jiunn-Chern; Yamasaki, Kazuhiko; Akama, Tomoya O; Huang, Chun-Teng; Campos, Alexandre Rosa; Nagaoka, Masato; Sasai, Toshio; Kimura-Takagi, Itsuko; Suwa, Yoichi; Yaegashi, Takashi; Shibata, Toshiaki K; Sugihara, Kazuhiro; Nishizawa-Harada, Chizuko; Fukuda, Minoru; Fukuda, Michiko N.
Afiliación
  • Nonaka M; Cancer Center, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
  • Suzuki-Anekoji M; Laboratory for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki, 305-8568, Japan.
  • Nakayama J; Department of Biological Chemistry, Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
  • Mabashi-Asazuma H; Cancer Center, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
  • Jarvis DL; Department of Molecular Pathology, Shinshu University School of Medicine, Matsumoto, 390-8621, Japan.
  • Yeh JC; Department of Molecular Biology, University of Wyoming, Laramie, WY, 82071, USA.
  • Yamasaki K; Department of Molecular Biology, University of Wyoming, Laramie, WY, 82071, USA.
  • Akama TO; Cancer Center, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
  • Huang CT; Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki, 305-8566, Japan.
  • Campos AR; Department of Pharmacology, Kansai Medical University, Hirakata, Osaka, 573-1010, Japan.
  • Nagaoka M; Cancer Center, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
  • Sasai T; Cancer Center, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
  • Kimura-Takagi I; Yakult Central Institute, Kunitachi, Tokyo, 186-8650, Japan.
  • Suwa Y; Yakult Central Institute, Kunitachi, Tokyo, 186-8650, Japan.
  • Yaegashi T; Yakult Central Institute, Kunitachi, Tokyo, 186-8650, Japan.
  • Shibata TK; Yakult Central Institute, Kunitachi, Tokyo, 186-8650, Japan.
  • Sugihara K; Yakult Central Institute, Kunitachi, Tokyo, 186-8650, Japan.
  • Nishizawa-Harada C; Cancer Center, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
  • Fukuda M; Department of Gynecology and Obstetrics, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan.
  • Fukuda MN; Department of Gynecology and Obstetrics, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan.
Br J Cancer ; 123(11): 1633-1643, 2020 11.
Article en En | MEDLINE | ID: mdl-32921792
BACKGROUND: Annexin A1 is expressed specifically on the tumour vasculature surface. Intravenously injected IF7 targets tumour vasculature via annexin A1. We tested the hypothesis that IF7 overcomes the blood-brain barrier and that the intravenously injected IF7C(RR)-SN38 eradicates brain tumours in the mouse. METHODS: (1) A dual-tumour model was generated by inoculating luciferase-expressing melanoma B16 cell line, B16-Luc, into the brain and under the skin of syngeneic C57BL/6 mice. IF7C(RR)-SN38 was injected intravenously daily at 7.0 µmoles/kg and growth of tumours was assessed by chemiluminescence using an IVIS imager. A similar dual-tumour model was generated with the C6-Luc line in immunocompromised SCID mice. (2) IF7C(RR)-SN38 formulated with 10% Solutol HS15 was injected intravenously daily at 2.5 µmoles/kg into two brain tumour mouse models: B16-Luc cells in C57BL/6 mice, and C6-Luc cells in nude mice. RESULTS: (1) Daily IF7C(RR)-SN38 injection suppressed tumour growth regardless of cell lines or mouse strains. (2) Daily injection of Solutol-formulated IF7C(RR)-SN38 led into complete disappearance of B16-Luc brain tumour in C57BL/6 mice, whereas this did not occur in C6-Luc in nude mice. CONCLUSIONS: IF7C(RR)-SN38 crosses the blood-brain barrier and suppresses growth of brain tumours in mouse models. Solutol HS15-formulated IF7C(RR)-SN38 may have promoted an antitumour immune response.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Portadores de Fármacos / Barrera Hematoencefálica / Anexina A1 / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: Br J Cancer Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Portadores de Fármacos / Barrera Hematoencefálica / Anexina A1 / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: Br J Cancer Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido